High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression

Brain Pathology

Volumn 24, Issue 2, 2014, Pages 184-189

  Goutagny, Stéphane ^a,b   Nault, Jean C ^b   Mallet, Maxime ^b   Henin, Dominique ^c,d   Rossi, Jessica Z ^b,d,e   Kalamarides, Michel ^b,f,g  

^a BEAUJON HOSPITAL   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

Author keywords

malignant progression; meningioma; neurofibromatosis type 2; TERT promoter

Indexed keywords

TELOMERASE; TERT PROTEIN, HUMAN;

DISEASE COURSE; FEMALE; GENETICS; HUMAN; INCIDENCE; MALE; MENINGIOMA; METABOLISM; MIDDLE AGED; MUTATION; PROMOTER REGION; TUMOR RECURRENCE;

DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84894271589     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12110     Document Type: Article

References (42)

1. Aavikko M, Li SP, Saarinen S, Alhopuro P, Kaasinen E, Morgunova E, et al (2012) Loss of SUFU function in familial multiple meningioma. Am J Hum Genet 91: 520-526.
2. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126: 267-276.
3. Boldrini L, Pistolesi S, Gisfredi S, Ursino S, Lupi G, Caniglia M, et al (2003) Telomerase in intracranial meningiomas. Int J Mol Med 12: 943-947.
4. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, et al (2001) Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)) p14(ARF) CDKN2B (p15(INK4b)) and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas. Am J Pathol 159: 661-669.
5. Brastianos PK, Horowitz PM, Santagata S, Jones RT, McKenna A, Getz G, et al (2013) Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 45: 285-289.
6. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al (2013) The somatic genomic landscape of glioblastoma. Cell 155: 462-477.
7. Cabuy E, de Ridder L, (2001) Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. Virchows Arch 439: 176-184.
8. Carroll T, Maltby E, Brock I, Royds J, Timperley W, Jellinek D, (1999) Meningiomas dicentric chromosomes gliomas and telomerase activity. J Pathol 188: 395-399.
9. Chen HJ, Liang CL, Lu K, Lin JW, Cho CL, (2000) Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer 89: 2092-2098.
10. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al (2013) Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7 KLF4 AKT1 and SMO. Science 339: 1077-1080.
11. DeMasters BK, Markham N, Lillehei KO, Shroyer KR, (1997) Differential telomerase expression in human primary intracranial tumors. Am J Clin Pathol 107: 548-554.
12. Falchetti ML, Larocca LM, Pallini R, (2002) Telomerase in brain tumors. Childs Nerv Syst 18: 112-117.
13. Falchetti ML, Pallini R, Larocca LM, Verna R, DAmbrosio E, (1999) Telomerase expression in intracranial tumours: prognostic potential for malignant gliomas and meningiomas. J Clin Pathol 52: 234-236.
14. Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, et al (2010) Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clin Cancer Res 16: 4155-4164.
15. Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N, (1998) Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 58: 2117-2125.
16. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339: 959-961.
17. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA, (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339: 957-959.
18. Kalala JPO, Maes L, Vandenbroecke C, de Ridder L, (2005) The hTERT protein as a marker for malignancy in meningiomas. Oncol Rep 13: 273-277.
19. Kheirollahi M, Mehrazin M, Kamalian N, Mohammadi-asl J, Mehdipour P, (2013) Telomerase activity in human brain tumors: astrocytoma and meningioma. Cell Mol Neurobiol 33: 569-574.
20. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A 110: 6021-6026.
21. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW, et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126: 907-915.
22. Langford LA, Piatyszek MA, Xu R, Schold SC, Wright WE, Shay JW, (1997) Telomerase activity in ordinary meningiomas predicts poor outcome. Hum Pathol 28: 416-420.
23. Leuraud P, Dezamis E, Aguirre-Cruz L, Taillibert S, Lejeune J, Robin E, et al (2004) Prognostic value of allelic losses and telomerase activity in meningiomas. J Neurosurg 100: 303-309.
24. Li JT, Bian K, Zhang AL, Kim DH, Ashley WW, Nath R, et al (2011) Targeting different types of human meningioma and glioma cells using a novel adenoviral vector expressing GFP-TRAIL fusion protein from hTERT promoter. Cancer Cell Int 11: 35.
25. Maes L, Kalala JPO, Cornelissen M, De Ridder L, (2006) PCNA Ki-67 and hTERT in residual benign meningiomas. In Vivo 20: 271-275.
26. van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJM, (2012) Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. Neurogenetics 13: 1-7.
27. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al (2013) High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun 4: 2218.
28. Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P, Ohgaki H, (2013) TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol 126: 931-937.
29. Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncol 15 (Suppl. 2): ii1-ii56.
30. Perry A, Banerjee R, Lohse CM, Kleinschmidt-DeMasters BK, Scheithauer BW, (2002) A role for chromosome 9p21 deletions in the malignant progression of meningiomas and the prognosis of anaplastic meningiomas. Brain Pathol 12: 183-190.
31. Peyre M, Stemmer-Rachamimov A, Clermont-Taranchon E, Quentin S, El-Taraya N, Walczak C, et al (2012) Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Oncogene 32: 4264-4272.
32. Pistolesi S, Boldrini L, Gisfredi S, Ieso KD, Camacci T, Caniglia M, et al (2004) Immunohistochemical and molecular study of radiation-induced multiple meningiomas with pleural and pulmonary metastasis. Tumori 90: 328-332.
33. Reuss DE, Piro RM, Jones DTW, Simon M, Ketter R, Kool M, et al (2013) Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 125: 351-358.
34. Riemenschneider MJ, Perry A, Reifenberger G, (2006) Histological classification and molecular genetics of meningiomas. Lancet Neurol 5: 1045-1054.
35. Ruden M, Puri N, (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39: 444-456.
36. Rushing EJ, Colvin SM, Gazdar A, Miura N, White C 3rd, Coimbra C, Burns DK, (1999) Prognostic value of proliferation index and expression of the RNA component of human telomerase (hTR) in papillary meningiomas. J Neurooncol 45: 199-207.
37. Sahm F, Bissel J, Koelsche C, Schweizer L, Capper D, Reuss D, et al (2013) AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathol 126: 757-762.
38. Sano T, Asai A, Mishima K, Fujimaki T, Kirino T, (1998) Telomerase activity in 144 brain tumours. Br J Cancer 77: 1633-1637.
39. Simon M, Park TW, Leuenroth S, Hans VH, Löning T, Schramm J, (2000) Telomerase activity and expression of the telomerase catalytic subunit hTERT in meningioma progression. J Neurosurg 92: 832-840.
40. Smith MJ, OSullivan J, Bhaskar SS, Hadfield KD, Poke G, Caird J, et al (2013) Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 45: 295-298.
41. Tallet A, Nault J-C, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al (2013) Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene [Epub ahead of print; doi: 10.1038/onc.2013.351 ].
42. Weber RG, Boström J, Wolter M, Baudis M, Collins VP, Reifenberger G, Lichter P, (1997) Analysis of genomic alterations in benign atypical and anaplastic meningiomas: toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94: 14719-14724.